Molecular targeted therapy for HER2 negative gastric cancer

doi:10.3760/cma.j.issn.1673422X.2016.12.016

Abstract

Abstract: Molecular targeted treatment has become hotspot in the gastric cancer research. Human epidermal growth factor receptor-2(HER-2) target genes found to treatment has widely used in clinical practice, and HER-2 positive incidence of less than 20%. In addition to HER-2, understanding the molecular pathways that characterize in cell growth, invasion and angiogenesis of targets and targeted therapy are worthy for attention.There are some molecular targeted drugs have been used to treat tumors,and patients can benefit from the treatment which brings new hope for patients with HER-2 negative gastric cancer.

Key words: Stomach neoplasms, Receptor, epidermal growth factor, Molecular targeted therapy

PENG Pai, YI Shan-Yong, ZHAO Ling. Molecular targeted therapy for HER2 negative gastric cancer[J]. Journal of International Oncology, 2016, 43(12): 943-946.

References

［1］ Ohtsu A,Shah MA,Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: a randomized，doubleblind，placebocontrolled phase Ⅲ study［J］. J Clin Oncol， 2011， 29(30): 39683976. DOI: 10.1200/JCO.2011.36.2236. ［2］ Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor2: an update on ramucirumab［J］. Expert Opin Biol Ther, 2013, 13（8）: 11871196. DOI: 10.1517/14712598.2013.810717. ［3］ Wilke H, Cutsem EV, Sang Cheul S, et al. RAINBOW: a global, phase Ⅲ, randomized, doubleblind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on firstline platinumand fluoropyrimidine containing combination therapy rainbow IMCL CP120922 (I4TIEJVBE) ［R/OL］. ［20140307］. http://meetinglibrary.asco.org/content/123363143. ［4］ Li J， Qin S， Xu J， et al． Apatinib for chemotherapyrefractory advanced metastatic gastric cancer: results from a randomized， placebocontrolled， parallelarm，phase Ⅱ trial［J］． J Clin Oncol, 2013, 31(26): 32193225．DOI: 10.1200/JCO.2013.48.8585. ［5］ Geng R, Li J. Apatinib for the treatment of gastric cancer［J］. Expert Opin Pharmacother, 2015, 16(1): 117122. DOI: 10.1517/14656566. 2015.981526. ［6］ Xing CG, Zhu BS, Fan X, et al. Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice［J］.World J Gastroenterol, 2009, 15(40): 50445052. DOI: 10.3748/wjg.15.5044. ［7］ Doi T， Muro K， Boku N， et al． Multicenter phase Ⅱ study of everolimus in patients with previously treated metastatic gastric cancer［J］． J Clin Oncol, 2010, 28 (11): 19041910. DOI: 10.1200/JCO.2009.26.2923. ［8］ Shen YC, Li CP, Yen CJ, et al. Phase Ⅱ multicentered study of lowdose everolimus plus cisplatin and weekly 24hour infusion of highdose 5fluorouracil and leucovorin as firstline treatment for patients with advanced gastric cancer［J］. Oncology, 2014, 87(2): 104113. DOI: 10.1159/000362671. ［9］ Wu JG, Yu JW, Wu HB, et al． Expressions and clinical significances of cMet,pMet and E2f1 in human gastric carcinoma［J］．BMC Res Notes, 2014, 7: 6. DOI: 10.1186/1756050076. ［10］ Doshi S, Gisleskog PO, Zhang Y，et al． Rilotumumab exposureresponse relationship in patients with advanced or metastatic gastric cancer［J］. Clin Cancer Res, 2015, 21(11): 24532461. DOI: 10.1158/10780432.CCR141661. ［11］ Iveson T, Donehower RC, Davidenko I, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as firstline treatment for gastric or oesophagogastric junction adenocarcinoma: an openlabel, dose deescalation phase 1b study and a doubleblind, randomised phase 2 study［J］. Lancet Oncol， 2014, 15(9): 10071018. DOI: 10.1016/S14702045(14)700233. ［12］ Catenacci DV， Henderson L， Xiao SY， et al．Durable completeresponse of metastatic gastric cancer with antiMet therapy followed by resistance at recurrence［J］. Cancer Discov, 2011, 1(7): 573579.DOI: 10.1158/21598290. ［13］ Cunningham D, Bang YJ, Tabernero J, et al. MetGastric: a randomized phase Ⅲ study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2negative and metpositive adenocarcinoma of the stomach or gastroesophageal junction［R/OL］. ［20140307］. http://meetinglibrary.asco.org/content/114845132. ［14］ Scagliotti GV, Novello S, von Pawel J. The emerging role of Met/HGF inhibitors in oncology［J］. Cancer Treat Rev, 2013, 39(7): 793801. DOI: 10.1016/j.ctrv.2013.02.001. ［15］ Shah MA， Wainberg ZA， Catenacci DV， et al．PhaseⅡstudy evaluating 2 dosing schedules of oral foretinib ( GSK1363089),cMet /VEGFR2 inhibitor,in patients with metastatic gastric cancer［J］. PLoS One, 2013, 8(3): e54014. DOI: 10.1371/journal.pone.0054014. ［16］ Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and cooccurrence among distinct therapeutic targets［J］. Gut, 2012, 61(5): 673684．DOI: 10.1136/gutjnl2011301839. ［17］ Li J, Ye Y, Wang M, et al. The overexpression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5fluorouracil towards gastric cancer［J］. Tumour Biol， 2016， 37(5): 68816891. DOI: 10.1007/ s1327701544111. ［18］ Yamada Y, Kiyota N, Fuse N, et al. A phase Ⅰ study of sorafenib in combination with S1 plus cisplatin in patients with advancedgastric cancer［J］. Gastric Cancer, 2014, 17（1）: 161172. DOI: 10.1007/s1012001302479. ［19］ Bang YJ, Im SA, Lee KW, et al．Randomized, doubleblind phase Ⅱ trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxelin patients with recurrent or metastatic gastric cancer［J］. J Clin Oncol， 2015, 33(33): 38583865. DOI: 10.1200/JCO.2014.60.0320. ［20］ Muro K, Chung HC, Shankaran V,et al．Pembrolizumab for patients with PDL1positive advanced gastric cancer(KEYNOTE012): a multicentre, openlabel, phase 1b trial［J］. Lancet Oncol, 2016, 17(6): 717726. DOI: 10.1016/S14702045(16)001753.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[4]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[5]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[6]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[7]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[8]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[9]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[10]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong. Progress of PARP inhibitors in targeted therapy of small cell lung cancer [J]. Journal of International Oncology, 2023, 50(6): 368-372.
[13]	Liu Bohan, Huang Junxing. Research progress of solute carriers related genes in malignant tumors [J]. Journal of International Oncology, 2023, 50(5): 280-284.
[14]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[15]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.